Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: A retrospective study over 8 years

Mycoses

Volumn 56, Issue 1, 2013, Pages 56-60

  Murat, Jean Benjamin ^a,b   Lebeau, Bernadette ^a   Chumpitazi, Bernabé ^a   Cornet, Muriel ^a,b   Maubon, Danièle ^a,b   Faure, Odile ^a   Quesada, Jean Louis ^a   Thiebaut Bertrand, Anne ^a   Timsit, Jean François ^a,b   Pelloux, Hervé ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

Amphotericin B; Antifungal agents; Candida krusei; Minimum inhibitory concentrations

Indexed keywords

AMPHOTERICIN B;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA KRUSEI; EPIDEMIOLOGY; FEMALE; FRANCE; FUNGUS ISOLATION; HOSPITAL DEPARTMENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CHILD, PRESCHOOL; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES;

ISSATCHENKIA ORIENTALIS;

EID: 84871607156     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02200.x     Document Type: Article

References (23)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
2. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-7.
3. Leroy O, Gangneux J-P, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
4. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-9.
5. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-51.
6. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
7. Barry AL, Pfaller MA, Brown SD et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457-9.
8. Pfaller MA, Messer SA, Bolmström A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis 1998; 32: 223-7.
9. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4, 936 clinical isolates of Candida species. J Clin Microbiol 2004; 42: 4977-9.
10. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2.
11. Bourgeois N, Dehandschoewercker L, Bertout S, Bousquet P-J, Rispail P, Lachaud L. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 System with the CLSI broth microdilution and E-test methods. J Clin Microbiol 2010; 48: 154-61.
12. Mallié M, Bastide JM, Blancard A et al. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents 2005; 25: 321-8.
13. Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses 2004; 47: 177-83.
14. Yang Y-L, Ho Y-A, Cheng H-H, Ho M, Lo H-J. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004; 25: 60-4.
15. Yang Y-L, Cheng H-H, Lo H-J. Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med Mycol 2006; 44: 237-42.
16. Yang Y-L, Wang A-H, Wang C-W, Cheng W-T, Li S-Y, Lo H-J. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Diagn Microbiol Infect Dis 2008; 61: 175-80.
17. Yang YL, Cheng MF, Wang CW et al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med Mycol 2010; 48: 328-34.
18. Panizo MM, Reviákina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 2009; 47: 137-43.
19. Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MAO. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 2005; 20: 349-53.
20. Pfaller MA, Diekema DJ, Gibbs DL et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-21.
21. Fournier P, Schwebel C, Maubon D et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 2011; 66: 2880-6.
22. Colodner R, Nuri Y, Chazan B, Raz R. Community-acquired and hospital-acquired candiduria: comparison of prevalence and clinical characteristics. Eur J Clin Microbiol Infect Dis 2008; 27: 301-5.
23. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-6.